A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies

Sponsor
Incyte

Protocol Number
Incyte INCAGN 1876-201

To Learn More Call
201-510-0910